Takeda Historical Income Statement

TAK Stock

USD 13.62 0.05 0.37%

Historical analysis of Takeda Pharmaceutical income statement accounts such as Gross Profit of 1.5 T, Other Operating Expenses of 4.3 T, Operating Income of 225 B or Ebit of 253.2 B can show how well Takeda Pharmaceutical Co performed in making a profits. Evaluating Takeda Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Takeda Pharmaceutical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Takeda Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Takeda Pharmaceutical is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Takeda Income Statement Analysis

Takeda Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Takeda Pharmaceutical shareholders. The income statement also shows Takeda investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Takeda Pharmaceutical Income Statement Chart

At this time, Takeda Pharmaceutical's EBIT is quite stable compared to the past year. Cost Of Revenue is expected to rise to about 1.5 T this year, although the value of EBITDA will most likely fall to about 587.4 B.

Selling General Administrative Gross Profit Other Operating Expenses Non Recurring Effect Of Accounting Charges

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Takeda Pharmaceutical Co minus its cost of goods sold. It is profit before Takeda Pharmaceutical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Takeda Pharmaceutical. It is also known as Takeda Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Takeda Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
Interest Expense	166.6B	169.7B	119.5B	125.5B
Depreciation And Amortization	583.2B	664.4B	728.0B	764.4B

Interest Expense Depreciation And Amortization

Takeda Pharmaceutical income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling And Marketing Expenses	Research Development	Net Income From Continuing Ops	Minority Interest	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.85	0.77	0.99	0.85	0.99	0.45	0.4	0.79	0.98	0.98	0.03	-0.95	0.4	-0.61	-0.14	0.88	0.64	-0.33	-0.54	-0.94	0.31	0.96
Interest Expense	0.85		0.68	0.82	0.83	0.77	0.65	0.57	0.86	0.79	0.75	0.29	-0.9	0.6	-0.4	-0.31	0.71	0.81	-0.28	-0.33	-0.9	0.67	0.88
Selling General Administrative	0.77	0.68		0.77	0.84	0.74	0.52	0.42	0.77	0.72	0.74	0.18	-0.79	0.46	-0.41	0.3	0.75	0.53	-0.22	-0.39	-0.74	0.3	0.8
Total Revenue	0.99	0.82	0.77		0.85	0.99	0.49	0.44	0.8	0.99	0.98	0.07	-0.94	0.43	-0.56	-0.14	0.89	0.66	-0.3	-0.51	-0.92	0.29	0.95
Gross Profit	0.85	0.83	0.84	0.85		0.82	0.56	0.49	0.9	0.8	0.82	0.21	-0.85	0.47	-0.38	-0.17	0.91	0.68	-0.25	-0.27	-0.81	0.43	0.91
Other Operating Expenses	0.99	0.77	0.74	0.99	0.82		0.37	0.33	0.73	0.98	1.0	-0.06	-0.92	0.31	-0.64	-0.14	0.88	0.57	-0.3	-0.58	-0.9	0.2	0.93
Operating Income	0.45	0.65	0.52	0.49	0.56	0.37		0.94	0.82	0.45	0.32	0.88	-0.53	0.95	0.24	-0.05	0.42	0.83	-0.18	0.19	-0.52	0.71	0.56
Ebit	0.4	0.57	0.42	0.44	0.49	0.33	0.94		0.81	0.41	0.28	0.87	-0.5	0.87	0.36	-0.05	0.37	0.72	-0.17	0.33	-0.46	0.57	0.5
Ebitda	0.79	0.86	0.77	0.8	0.9	0.73	0.82	0.81		0.76	0.7	0.54	-0.84	0.73	-0.12	-0.14	0.8	0.81	-0.28	-0.07	-0.81	0.57	0.88
Cost Of Revenue	0.98	0.79	0.72	0.99	0.8	0.98	0.45	0.41	0.76		0.96	0.03	-0.93	0.4	-0.6	-0.16	0.89	0.61	-0.32	-0.57	-0.93	0.24	0.95
Total Operating Expenses	0.98	0.75	0.74	0.98	0.82	1.0	0.32	0.28	0.7	0.96		-0.11	-0.9	0.26	-0.66	-0.13	0.87	0.55	-0.29	-0.57	-0.87	0.18	0.9
Income Before Tax	0.03	0.29	0.18	0.07	0.21	-0.06	0.88	0.87	0.54	0.03	-0.11		-0.11	0.88	0.6	0.04	0.07	0.6	-0.03	0.53	-0.08	0.65	0.16
Total Other Income Expense Net	-0.95	-0.9	-0.79	-0.94	-0.85	-0.92	-0.53	-0.5	-0.84	-0.93	-0.9	-0.11		-0.46	0.54	0.14	-0.82	-0.66	0.33	0.53	0.96	-0.38	-0.95
Net Income	0.4	0.6	0.46	0.43	0.47	0.31	0.95	0.87	0.73	0.4	0.26	0.88	-0.46		0.15	-0.02	0.35	0.82	-0.12	0.13	-0.45	0.75	0.5
Income Tax Expense	-0.61	-0.4	-0.41	-0.56	-0.38	-0.64	0.24	0.36	-0.12	-0.6	-0.66	0.6	0.54	0.15		0.12	-0.45	-0.11	0.13	0.88	0.57	0.09	-0.51
Selling And Marketing Expenses	-0.14	-0.31	0.3	-0.14	-0.17	-0.14	-0.05	-0.05	-0.14	-0.16	-0.13	0.04	0.14	-0.02	0.12		-0.14	-0.29	-0.22	0.0	0.17	-0.2	-0.16
Research Development	0.88	0.71	0.75	0.89	0.91	0.88	0.42	0.37	0.8	0.89	0.87	0.07	-0.82	0.35	-0.45	-0.14		0.55	-0.36	-0.41	-0.81	0.25	0.93
Net Income From Continuing Ops	0.64	0.81	0.53	0.66	0.68	0.57	0.83	0.72	0.81	0.61	0.55	0.6	-0.66	0.82	-0.11	-0.29	0.55		-0.14	0.01	-0.63	0.82	0.67
Minority Interest	-0.33	-0.28	-0.22	-0.3	-0.25	-0.3	-0.18	-0.17	-0.28	-0.32	-0.29	-0.03	0.33	-0.12	0.13	-0.22	-0.36	-0.14		0.19	0.39	-0.11	-0.38
Tax Provision	-0.54	-0.33	-0.39	-0.51	-0.27	-0.58	0.19	0.33	-0.07	-0.57	-0.57	0.53	0.53	0.13	0.88	0.0	-0.41	0.01	0.19		0.56	0.17	-0.49
Net Interest Income	-0.94	-0.9	-0.74	-0.92	-0.81	-0.9	-0.52	-0.46	-0.81	-0.93	-0.87	-0.08	0.96	-0.45	0.57	0.17	-0.81	-0.63	0.39	0.56		-0.34	-0.95
Interest Income	0.31	0.67	0.3	0.29	0.43	0.2	0.71	0.57	0.57	0.24	0.18	0.65	-0.38	0.75	0.09	-0.2	0.25	0.82	-0.11	0.17	-0.34		0.38
Reconciled Depreciation	0.96	0.88	0.8	0.95	0.91	0.93	0.56	0.5	0.88	0.95	0.9	0.16	-0.95	0.5	-0.51	-0.16	0.93	0.67	-0.38	-0.49	-0.95	0.38

Click cells to compare fundamentals

Takeda Pharmaceutical Account Relationship Matchups

Takeda Pharmaceutical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	587.5B	559.7B	583.2B	664.4B	728.0B	764.4B
Interest Expense	165.0B	248.6B	166.6B	169.7B	119.5B	125.5B
Selling General Administrative	964.7B	875.7B	886.4B	997.3B	1.1T	783.0B
Total Revenue	3.3T	3.2T	3.6T	4.0T	4.3T	4.5T
Gross Profit	2.2T	2.2T	2.5T	2.8T	2.8T	1.5T
Other Operating Expenses	3.2T	2.7T	3.1T	3.5T	4.0T	4.3T
Operating Income	100.4B	509.3B	460.8B	490.5B	214.1B	225.0B
Ebit	100.4B	424.0B	600.1B	492.1B	172.3B	253.2B
Ebitda	687.9B	983.7B	1.2T	1.2T	900.3B	587.4B
Cost Of Revenue	1.1T	994.3B	1.1T	1.2T	1.4T	1.5T
Total Operating Expenses	2.1T	1.7T	2.0T	2.3T	2.6T	2.7T
Income Before Tax	(60.8B)	366.2B	302.6B	375.1B	52.8B	50.2B
Total Other Income Expense Net	(161.2B)	(143.0B)	(158.3B)	(115.4B)	(161.3B)	(153.2B)
Net Income	44.2B	376.0B	230.1B	317.0B	144.1B	158.1B
Income Tax Expense	(105.0B)	(9.9B)	72.4B	58.1B	(91.4B)	(86.8B)
Research Development	492.4B	455.8B	526.1B	633.3B	729.9B	480.1B
Net Income From Continuing Ops	44.3B	376.2B	230.2B	317.0B	144.2B	167.4B
Net Income Applicable To Common Shares	44.2B	376.0B	230.1B	317.0B	364.6B	382.8B
Minority Interest	4.0B	4.1B	(107M)	(21M)	(130M)	(123.5M)
Tax Provision	(105.0B)	(9.9B)	72.4B	58.1B	(91.4B)	(86.8B)
Net Interest Income	(146.6B)	(143.1B)	(142.9B)	(106.8B)	(140.5B)	(147.5B)
Interest Income	11.2B	105.5B	23.7B	62.9B	11.3B	10.7B
Reconciled Depreciation	583.6B	559.7B	583.2B	664.4B	728.0B	561.5B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:

How To Invest In Takeda

Details

Is Takeda Stock a good investment?

Details

What is Takeda Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.049

Dividend Share

192

Earnings Share

0.59

Revenue Per Share

1.4 K

Quarterly Revenue Growth

0.127

The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Takeda Historical Income Statement

About Takeda Income Statement Analysis

Takeda Pharmaceutical Income Statement Chart

Gross Profit

Other Operating Expenses

Takeda Pharmaceutical income statement Correlations

Takeda Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Takeda Pharmaceutical income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Total Revenue	+ 0.99	Depreciation And Amortization
Other Operating Expenses	+ 0.99	Depreciation And Amortization
Other Operating Expenses	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.98	Depreciation And Amortization

Reconciled Depreciation	- 0.95	Net Interest Income
Reconciled Depreciation	- 0.95	Total Other Income Expense Net
Total Other Income Expense Net	- 0.95	Depreciation And Amortization
Total Other Income Expense Net	- 0.94	Total Revenue
Net Interest Income	- 0.94	Depreciation And Amortization
Net Interest Income	- 0.93	Cost Of Revenue